MA
PCSA icon

MYDA Advisors’s Processa Pharmaceuticals PCSA Stock Holding History

MYDA Advisors’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-80
Closed -$265K – 324
2020
Q4 		$265K Buy
+80
New +$222K 0.08% 157

Other funds holding PCSA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MYDA Advisors's PCSA Position: Q1 2021 in Review

MYDA Advisors sold out of Processa Pharmaceuticals (PCSA) in Q1 2021, closing a stake of 80 shares — an estimated $265K sold.

MYDA Advisors first reported a position in PCSA in Q4 2020 and held it in 1 quarter. The position peaked at $265K in Q4 2020. 13 funds tracked by Wall St. Rank hold PCSA as of Q1 2021.

  • MYDA Advisors reported no remaining Processa Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • MYDA Advisors sold 80 Processa Pharmaceuticals shares in Q1 2021, an estimated $265K.
  • MYDA Advisors first reported a position in Processa Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • MYDA Advisors's Processa Pharmaceuticals position peaked at $265K in Q4 2020.
  • 13 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2021.

Based on MYDA Advisors's 13F filing for Q1 2021, filed 12 May 2021.